$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

$tsoi Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223029721 Filed on August 21, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$25.73K	$26.31K	$38.75K
YoY Change	-65.48%	-32.11%	65.28%
Cost Of Revenue	$7.052K	$10.70K	$8.709K
YoY Change	-19.77%	22.85%	113.14%
Gross Profit	$18.68K	$15.61K	$30.04K
YoY Change	-71.59%	-48.04%	55.18%
Gross Profit Margin	72.59%	59.33%	77.52%
Selling, General & Admin	$330.0K	$349.6K	$507.5K
YoY Change	-35.28%	-31.12%	63.35%
% of Gross Profit	1766.78%	2239.61%	1689.51%
Research & Development	$148.9K	$208.5K	$597.9K
YoY Change	-45.88%	-65.12%	352.66%
% of Gross Profit	797.08%	1336.02%	1990.32%
Depreciation & Amortization	$70.00K	$76.92K	$100.3K
YoY Change	-20.04%	-23.3%	3507.55%
% of Gross Profit	374.77%	492.79%	333.85%
Operating Expenses	$476.0K	$558.1K	$1.105M
YoY Change	-39.36%	-49.51%	149.65%
Operating Profit	-$457.3K	-$542.5K	-$1.075M
YoY Change	-36.41%	-49.55%	153.97%
Interest Expense	$83.06K	$122.3K	$195.4K
YoY Change	-50.37%	-37.43%	-0.35%
% of Operating Profit
Other Income/Expense, Net	-$145.5K	-$19.95K	-$115.4K
YoY Change	-35.74%	-82.71%	-46.04%
Pretax Income	-$602.9K	-$562.5K	-$1.191M
YoY Change	-36.25%	-52.76%	86.86%
Income Tax		$800.00
% Of Pretax Income
Net Earnings	-$602.0K	-$562.4K	-$1.191M
YoY Change	-36.39%	-52.77%	86.86%
Net Earnings / Revenue	-2339.84%	-2137.75%	-3073.0%
Basic Earnings Per Share	$0.00	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$468.50
COMMON SHARES
Basic Shares Outstanding	332.5M shares	3.022B shares	2.541B shares
Diluted Shares Outstanding	3.287B shares	2.976B shares	2.541B shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.00K	$123.1K	$197.3K
YoY Change	-4.51%	-37.61%	266.71%
Cash & Equivalents	$90.14K	$123.1K	$197.3K
Short-Term Investments
Other Short-Term Assets	$40.00K	$50.83K	$541.5K
YoY Change	-88.34%	-90.61%	190.98%
Inventory	$26.42K	$31.39K	$62.57K
Prepaid Expenses	$24.12K	$16.92K
Receivables	$21.76K	$17.58K	$31.84K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$181.0K	$222.9K	$833.2K
YoY Change	-65.5%	-73.25%	162.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$377.1K	$267.6K	$281.7K
YoY Change	6.48%	-4.99%	-10.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.785M	$2.859M	$3.405M
YoY Change	-15.58%	-16.04%	5849.68%
Total Long-Term Assets	$3.293M	$3.265M	$3.708M
YoY Change	-10.2%	-11.97%	628.82%
TOTAL ASSETS
Total Short-Term Assets	$181.0K	$222.9K	$833.2K
Total Long-Term Assets	$3.293M	$3.265M	$3.708M
Total Assets	$3.474M	$3.487M	$4.541M
YoY Change	-17.12%	-23.21%	449.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$380.0K	$362.6K	$361.6K
YoY Change	4.4%	0.27%	19.27%
Accrued Expenses	$601.4K	$569.9K	$515.0K
YoY Change	8.91%	10.65%	11.39%
Deferred Revenue
YoY Change
Short-Term Debt	$750.0K	$743.5K	$1.064M
YoY Change	-29.33%	-30.12%	5.54%
Long-Term Debt Due	$0.00	$4.640K	$4.640K
YoY Change	-100.0%	0.0%
Total Short-Term Liabilities	$2.053M	$1.875M	$2.314M
YoY Change	-14.26%	-18.99%	10.48%
LONG-TERM LIABILITIES
Long-Term Debt	$10.00K	$8.080K	$12.78K
YoY Change	-14.09%	-36.78%
Other Long-Term Liabilities	$110.0K	$113.5K	$2.150K
YoY Change	5016.28%	5180.93%	-92.3%
Total Long-Term Liabilities	$120.0K	$121.6K	$14.93K
YoY Change	770.2%	714.6%	-46.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.053M	$1.875M	$2.314M
Total Long-Term Liabilities	$120.0K	$121.6K	$14.93K
Total Liabilities	$2.165M	$1.996M	$2.329M
YoY Change	-10.11%	-14.29%	9.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.41M	-$18.81M	-$15.79M
YoY Change	16.03%	19.17%
Common Stock	$3.451M	$3.134M	$2.552M
YoY Change	33.33%	22.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.311M	$1.492M	$2.212M
YoY Change
Total Liabilities & Shareholders Equity	$3.474M	$3.487M	$4.541M
YoY Change	-17.12%	-23.21%	449.91%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$602.0K	-$562.4K	-$1.191M
YoY Change	-36.39%	-52.77%	86.86%
Depreciation, Depletion And Amortization	$70.00K	$76.92K	$100.3K
YoY Change	-20.04%	-23.3%	3507.55%
Cash From Operating Activities	-$310.0K	-$337.1K	-$236.5K
YoY Change	53.55%	42.55%	2.46%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$2.750K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$20.00K	-$2.750K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	300.0K	433.4K	268.9K
YoY Change	203.49%	61.2%	28.55%
NET CHANGE
Cash From Operating Activities	-310.0K	-337.1K	-236.5K
Cash From Investing Activities	-20.00K	-2.750K	0.000
Cash From Financing Activities	300.0K	433.4K	268.9K
Net Change In Cash	-30.00K	93.55K	32.38K
YoY Change	-70.89%	188.91%	-218.65%
FREE CASH FLOW
Cash From Operating Activities	-$310.0K	-$337.1K	-$236.5K
Capital Expenditures	$20.00K	$0.00	$0.00
Free Cash Flow	-$330.0K	-$337.1K	-$236.5K
YoY Change	63.46%	42.55%	3.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001419051
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	332482767	shares
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q2	TSOI	Intercompany Account IntercompanyAccount		usd
CY2022Q4	TSOI	Intercompany Account IntercompanyAccount		usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	TSOI	Payments For Proceeds From Notes Receivable PaymentsForProceedsFromNotesReceivable		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash		usd
CY2023Q2	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54554
	dei	Entity Registrant Name EntityRegistrantName	Therapeutic Solutions International, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1226465
	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Wild Rose Lane
	dei	Entity Address City Or Town EntityAddressCityOrTown	Elk City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	ID
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	83525
	dei	City Area Code CityAreaCode	(760)
	dei	Local Phone Number LocalPhoneNumber	295-7208
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123083	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18040	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17579	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25398	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	31392	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	42428	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50830	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	222884	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	309221	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267638	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	138202	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8612	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2858696	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2023Q2	us-gaap	Assets Assets	3487420	usd
CY2022Q4	us-gaap	Assets Assets	3605531	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	569875	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	531783	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24661	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8612	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	113442	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	175063	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	47808	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	65187	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	169440	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1874648	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2210237	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	8079	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	10507	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	113541	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1996268	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2220744	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4505000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4505000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3134044074	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3134044074	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2617390830	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2617390830	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3134045	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2617392	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17181978	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16334129	usd
CY2023Q2	TSOI	Shares To Be Issued SharesToBeIssued	9324	usd
CY2022Q4	TSOI	Shares To Be Issued SharesToBeIssued	126324	usd
CY2023Q2	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18812339	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17672058	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1492008	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-856	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1491152	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1384787	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3487420	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3605531	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26308	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38749	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49431	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	123647	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10699	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8709	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19165	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24647	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	15609	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	30040	usd
	us-gaap	Gross Profit GrossProfit	30266	usd
	us-gaap	Gross Profit GrossProfit	99000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	113343	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	143716	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	232744	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	183723	usd
CY2023Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	113954	usd
CY2022Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	112533	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	224479	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	226818	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	53473	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	142010	usd
	us-gaap	Professional Fees ProfessionalFees	122757	usd
	us-gaap	Professional Fees ProfessionalFees	229126	usd
CY2023Q2	us-gaap	Legal Fees LegalFees	68805	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	109271	usd
	us-gaap	Legal Fees LegalFees	161392	usd
	us-gaap	Legal Fees LegalFees	159363	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	208540	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	597893	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	261267	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	902052	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	558115	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1105423	usd
	us-gaap	Operating Expenses OperatingExpenses	1002639	usd
	us-gaap	Operating Expenses OperatingExpenses	1701082	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-542506	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1075383	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-972373	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1602082	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6141	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-43184	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	24275	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-109716	usd
CY2023Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	10624	usd
CY2022Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	123202	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-33712	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	265508	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	122261	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	195392	usd
	us-gaap	Interest Expense InterestExpense	244073	usd
	us-gaap	Interest Expense InterestExpense	345390	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	85546	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	85546	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19950	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-115374	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-167964	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-189598	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-562456	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1190757	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1140337	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1791680	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-563256	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1190757	usd
	us-gaap	Profit Loss ProfitLoss	-1141137	usd
	us-gaap	Profit Loss ProfitLoss	-1791680	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-856	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-856	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-562400	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1190757	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1140281	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1791680	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2976127083	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2976127083	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2541429204	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2541429204	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2834408024	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2834408024	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2468126294	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2468126294	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-804982	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	407200	usd
	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	148820	usd
	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	29999	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	445000	usd
	TSOI	Stock Issued During Period Value For License StockIssuedDuringPeriodValueForLicense	3107570	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	670513	usd
	us-gaap	Profit Loss ProfitLoss	-1791680	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2212440	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2305029	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	407200	usd
CY2022Q2	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	148820	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	442148	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1190757	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2212440	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1384787	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	79600	usd
	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	20000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	488352	usd
	TSOI	Adjustments To Additional Paid In Capital Subsidiary For Services AdjustmentsToAdditionalPaidInCapitalSubsidiaryForServices	1831	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	657719	usd
	us-gaap	Profit Loss ProfitLoss	-1141137	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1491152	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1165051	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1165051	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	358266	usd
CY2023Q2	TSOI	Adjustments To Additional Paid In Capital Subsidiary For Services AdjustmentsToAdditionalPaidInCapitalSubsidiaryForServices	1831	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	469260	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-563256	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1491152	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1491152	usd
	us-gaap	Profit Loss ProfitLoss	-1141137	usd
	us-gaap	Profit Loss ProfitLoss	-1791680	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	256600	usd
	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	79600	usd
	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	150600	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	24275	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-109716	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-33712	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	265508	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	85546	usd
	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	101162	usd
	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	624165	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	221686	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	313917	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148387	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104805	usd
	us-gaap	Depreciation Depreciation	5441	usd
	us-gaap	Depreciation Depreciation	2326	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7819	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15224	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11036	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	22749	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-70528	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28785	usd
	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	16654	usd
	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	12654	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-46615	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-32440	usd
	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	-6	usd
	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	-2566	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	80026	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	87899	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16654	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12654	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-538182	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-451354	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000	usd
	TSOI	Payments For Proceeds From Notes Receivable PaymentsForProceedsFromNotesReceivable	800	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-800	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	12	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2430	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3360	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	143750	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	315000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2428	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2186	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	488352	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	445000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	633022	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	755384	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	94040	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	104030	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29043	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104259	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	123083	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	208289	usd
	us-gaap	Interest Paid Net InterestPaidNet	2091	usd
	us-gaap	Interest Paid Net InterestPaidNet	229126	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1570	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	17500	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	22500	usd
	TSOI	Debt Discount Recorded In Connection With Derivative Liability DebtDiscountRecordedInConnectionWithDerivativeLiability	142565	usd
	TSOI	Debt Discount Recorded In Connection With Derivative Liability DebtDiscountRecordedInConnectionWithDerivativeLiability	315000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	657719	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	670513	usd
	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	1831	usd
	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	148820	usd
	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	20000	usd
	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	29999	usd
	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	9170	usd
	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	12958	usd
	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue	3107570	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	146244	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123083	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197286	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123083	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	208289	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_802_eus-gaap--NatureOfOperations_zQmsvlkKeTXi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 1 – <span id="xdx_822_zCLeAhSk9oUj">Organization and Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized <span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_c20230101__20230630_z5YH7SBLWFx4" title="Entity incorporation date">August 6, 2007</span>, under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Business Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Nutraceutical Division</b> – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. QuadraMune has been shown to increase Natural Killer Cell activity and healthy Cytokine production. Our synergistic blend of ingredients helps the immune system fight off common and complex ailments and promote healthy T Cell activity. Recently the Company was approved to sell certain nutraceuticals on the Amazon Platform.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Cellular Division</b> – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, <span id="xdx_901_eus-gaap--UnusualOrInfrequentItemNatureOfEventOrTransaction_c20210803__20210804_zaUNaQrhB5ad" title="Unusual or infrequent item, description">the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%</span>. The Company also recently announced the launching of Phase III for IND # 19757 with Biorasi LLC, a global, full-service CRO, who will run the clinical trial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Most recently the Company announced filing of a patent application covering the use stem cell derived exosomes for treatment of aortic aneurysms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>June 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Management does not expect existing cash as of June 30, 2023, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2023, the Company has incurred losses totaling $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20070806__20230630_zPK4eY839Rd" title="Net income loss">18.8</span> million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2007-08-06
CY2021Q3	us-gaap	Unusual Or Infrequent Item Nature Of Event Or Transaction UnusualOrInfrequentItemNatureOfEventOrTransaction	the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%
	us-gaap	Net Income Loss NetIncomeLoss	-18800000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	138202	usd
	TSOI	Wholesale Purchase Price And Payments Description WholesalePurchasePriceAndPaymentsDescription	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	258162	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2854573	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3002960	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148387	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104805	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	169440	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	202144	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	188043	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-254459	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	33712	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	169440	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zNGyfoBdc5w4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_86F_zRd0jfDXNU0k">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	586973744	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	167223808	shares
	us-gaap	Depreciation Depreciation	5441	usd
	us-gaap	Depreciation Depreciation	2326	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148387	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104805	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	261267	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	902052	usd
CY2023Q2	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	33340	usd
CY2022Q4	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	148550	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	572	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1141	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16918	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62661	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50830	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2023Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	4505000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3134044074	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301359	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301359	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33721	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28281	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267638	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
	us-gaap	Depreciation Depreciation	5441	usd
	us-gaap	Depreciation Depreciation	2326	usd
CY2022Q4	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	7537	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2023Q2	TSOI	Licenses Noncurrent LicensesNoncurrent	2854583	usd
CY2022Q4	TSOI	Licenses Noncurrent LicensesNoncurrent	3002960	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2858696	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	406549	usd
CY2022Q3	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-856	usd
CY2023Q1	us-gaap	Area Of Land AreaOfLand	1700	sqft
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P60M
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2028-04-30
	us-gaap	Payments For Rent PaymentsForRent	12604	usd
	us-gaap	Payments For Rent PaymentsForRent	12522	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure

Files In Submission

Name	View Source	Status
0001493152-23-029721-index-headers.html	Edgar Link	pending
0001493152-23-029721-index.html	Edgar Link	pending
0001493152-23-029721.txt	Edgar Link	pending
0001493152-23-029721-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsoi-20230630.xsd	Edgar Link	pending
tsoi-20230630_cal.xml	Edgar Link	unprocessable
tsoi-20230630_def.xml	Edgar Link	unprocessable
tsoi-20230630_lab.xml	Edgar Link	unprocessable
tsoi-20230630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2023 Q3 Form 10-Q Financial Statement

#000149315223029721 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2023 Q3 Form 10-Q Financial Statement

#000149315223029721 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi